RISE登记研究揭示生物制剂及靶向合成DMARDs新用药者用药安全筛查存在缺口
基于美国风湿病学会RISE登记系统,纳入26802例生物制剂或靶向合成DMARDs新用药者,评估治疗前乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)及结核(TB)筛查率。结果显示仅15.5%患者完成所有适用感染筛查,实践层面复合筛查率范围0至48.3%,2.4%筛查试验阳性。
要点
- 仅15.5%新用药者治疗前完成所有适用感染筛查。
- HBV和HCV任何筛查记录率分别为44.8%和40.5%。
- 实践层面复合筛查率低,范围0至48.3%。
核心结论
- RISE登记参与实践中,生物制剂或靶向合成DMARDs新用药者的关键安全筛查记录存在缺口。
- 鉴于存在少量但显著的活动性或潜伏感染患者构成安全风险,开发标准化且可靠的筛查策略至关重要。
研究设计与样本
- 基于美国风湿病学会RISE登记系统的数据,纳入≥18岁生物制剂或靶向合成DMARDs新用药者。
- 开发了针对HBV、HCV和TB治疗前筛查的质量指标及所有适用检测的复合指标。
主要发现
- 共纳入全国213家风湿科实践的26802例患者,年龄58(14)岁,女性占75.9%。
- 59.6%患者患有类风湿关节炎,TNFi是最常见的索引DMARD(64.9%)。
- 索引日期前,44.8%患者有HBV任何筛查记录,40.5%有HCV任何筛查记录。
- 药物开始前一年内,29.7%患者有TB筛查记录。
- 仅15.5%患者在药物开始前有所有适用感染筛查的记录。
关键数值与推荐
- HBV任何筛查记录率44.8%,HCV任何筛查记录率40.5%,TB药物开始前一年内筛查率29.7%。
- 所有适用感染筛查的复合记录率15.5%,实践层面复合指标执行率范围0至48.3%。
- 筛查试验阳性率2.4%。
临床怎么用
- 对生物制剂或靶向合成DMARDs新用药者,应系统化落实HBV、HCV和TB治疗前筛查并完整记录。
- 参与登记实践的筛查执行率差异大,需标准化策略以捕捉安全筛查措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immunosuppressant drugs can increase the risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) and tuberculosis (TB) reactivation. Using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry, we examined pre-treatment screening among new users of biologic or targeted synthetic disease modifying drugs (DMARDs). METHODS: Data, derived from RISE, included patients ≥ 18 years old who were new users of biologic or targeted synthetic DMARDs. We developed quality measures related to pre-treatment screening for HBV, HCV, and TB in addition to a "composite" measure for all applicable tests. We assessed patient-level screening rates, practice-level variation among practices reporting on ≥ 20 patients, and the frequency of positive results. RESULTS: We included 26,802 patients across 213 rheumatology practices nationwide. Patients were 58 (14) years old, 75.9% female; 59.6% had rheumatoid arthritis, and TNFi were the most common index DMARDs (64.9%). Overall, 44.8% and 40.5% patients had any documented HBV or HCV screening, respectively, prior to the index date; 29.7% had TB screening in the year prior to drug start. Only 15.5% had documentation of screening for all appropriate infections prior to drug start. Practice-level performance on the composite measure was low (range 0 to 48.3%). 2.4% of screening tests were positive. CONCLUSION: We found gaps in documentation of key safety measures among practices participating in RISE. Given the small but significant number of patients with active or latent infections that pose safety risks, developing standardized and reliable strategies to capture safety screening measures is paramount.
引用
- Schmajuk G, Li J, Evans M, et al. RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. Semin Arthritis Rheum. 2020. PMID: 32234243. doi:10.1016/j.semarthrit.2020.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。